I think the concentration on now is to get some contracts. To put this company on the map then they can go after all the other programs that have been started. Just hoping to be well rewarded for our patience. Once. Interacts startvroling in. This is a new company
Cytocom is a private company. They are not obligated to update IMUN shareholders on the status of their trials. That powerpoint from www.cytocom.com/investors/ has not been updated in at least a year, maybe more, I'm not sure exactly.
It should serve as a bare minimum to investors at this point.
For me, as I speculate that IMUN is "Dump and Pump", therefore they demote rather than promote, the management not updating the powerpoint on www.cytocom.com, a private company, seems pretty in line with their mission of wanting to keep quiet and keep the stock price low. All my opinion. Why should they update it if they don't have to? They're clearly not trying to promote it, and there are no laws stating they have to update their info. It's a private company.
Noreen has said that IMUN shareholders will be updated on the status of all Cytocom trials "following the launch of Lodonal [in Nigeria]".
LDN for Crohn's has the potential to be the biggest revenue generator - I think. I could be wrong on that. LDN has been shown to be most effective for Crohn's though, compared to any other disease, I believe. However, that's Cytocom revenue so only about 1/8 of it is for IMUN shareholders (as of current structure).
News 
Market Data 
Discover 
